{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-24-000136","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.281081+00:00","generated_at":"2026-05-31T11:04:10.937225+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcus reports Q2 2024 net loss $93M, cash $1.0B; casdatifan data due Q4","bullets":["Revenue $39M (up from $29M in Q2 2023); net loss $93M vs $75M year-over-year.","Cash, cash equivalents and marketable securities $1.0B, sufficient into 2027; expects $885-925M by year-end 2024.","Casdatifan 100mg ccRCC expansion ORR data expected Q4 2024; PEAK-1 Phase 3 study start H1 2025.","STAR-221 (domvanalimab+chemo) completed enrollment; STAR-121 (NSCLC) expected to complete enrollment in 2024.","Taiho exercised option for quemliclustat in Japan/Asia; Phase 3 PRISM-1 pancreatic cancer to start early 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-24-000136","json":"https://secwatch.observer/filing/0001724521-24-000136.json","markdown":"https://secwatch.observer/filing/0001724521-24-000136.md","text":"https://secwatch.observer/filing/0001724521-24-000136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000136/0001724521-24-000136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000136/rcus-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:04:10.937225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}